CTI BioPharma Shares Drop 13% After Public Offering Prices
CTI BioPharma Shares Drop 13% After Public Offering Prices
DJ CTI BioPharma Shares Drop 13% After Public Offering Prices
By Chris Wack
CTI BioPharma Corp. shares were down 13% to $2.54 after the company priced its previously announced underwritten public offering of 14.3 million common shares and 600 shares of its series X1 preferred stock.
The company has granted the underwriters a 30-day option to purchase up to an additional 2.1 million shares.
The offering price to the public of a share of common stock is $2.50 and the offering price of series X1 stock is $25,000. Each share of series X1 stock will be convertible into 10,000 shares of common stock at the election of the holder.
All of the securities in the offering are being sold by CTI, which should see proceeds of $50.7 million from the offering.
The offering is expected to close on or about April 6.
CTI said it intends to use the proceeds from the proposed sale for commercialization activities for pacritinib, general working capital and corporate purposes.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
April 01, 2021 10:54 ET (14:54 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
DJ CTI BioPharma Shares Drop 13% After Public Offering Prices
DJ CTI BioPharma股价在公开募股价格后下跌13%
By Chris Wack
克里斯·瓦克(Chris Wack)著
CTI BioPharma Corp. shares were down 13% to $2.54 after the company priced its previously announced underwritten public offering of 14.3 million common shares and 600 shares of its series X1 preferred stock.
CTI BioPharma Corp.股价下跌13%，报2.54美元，此前该公司为之前宣布的1,430万股普通股和600股X1系列优先股的承销公开发行定价。
The company has granted the underwriters a 30-day option to purchase up to an additional 2.1 million shares.
该公司已授予承销商30天的选择权，最多可额外购买210万股票。
The offering price to the public of a share of common stock is $2.50 and the offering price of series X1 stock is $25,000. Each share of series X1 stock will be convertible into 10,000 shares of common stock at the election of the holder.
普通股的公开发行价为2.50美元，X1系列股票的发行价为2.5万美元。根据持有者的选择，X1系列股票的每股可转换为10,000股普通股。
All of the securities in the offering are being sold by CTI, which should see proceeds of $50.7 million from the offering.
此次发行的所有证券都由CTI出售，CTI应该会从此次发行中获得5070万美元的收益。
The offering is expected to close on or about April 6.
预计此次发行将于4月6日左右结束。
CTI said it intends to use the proceeds from the proposed sale for commercialization activities for pacritinib, general working capital and corporate purposes.
CTI表示，它打算将拟议出售的收益用于帕利替尼的商业化活动、一般营运资金和企业用途。
Write to Chris Wack at chris.wack@wsj.com
写信给克里斯·瓦克(chris.wack@wsj.com)
(END) Dow Jones Newswires
(完)道琼通讯社
April 01, 2021 10:54 ET (14:54 GMT)
2021年4月1日美国东部时间10：54(格林尼治标准时间14：54)
Copyright (c) 2021 Dow Jones & Company, Inc.
版权所有(C)2021年道琼斯公司
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧